Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2024 | 12-2023 | 09-2023 | 06-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 323,168 | 500,684 | 360,028 | 342,005 | 1,279,690 |
| Depreciation Amortization | 321,715 | 742,540 | 429,270 | 169,681 | 587,319 |
| Accounts receivable | -171,430 | -216,988 | -43,442 | 61,130 | -274,884 |
| Accounts payable and accrued liabilities | -147,686 | -95,370 | -203,253 | -242,119 | -110,512 |
| Other Working Capital | -549,683 | -769,298 | -547,377 | -353,225 | -779,530 |
| Other Operating Activity | 304,557 | 521,805 | 343,441 | 111,573 | 804,351 |
| Operating Cash Flow | $80,640 | $683,373 | $338,666 | $89,045 | $1,506,435 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -89,581 | -187,184 | -138,366 | -73,453 | -178,870 |
| Net Acquisitions | N/A | -5,336,531 | -5,244,352 | N/A | N/A |
| Purchase Of Investment | N/A | N/A | N/A | N/A | 86,393 |
| Purchase Sale Intangibles | -61,645 | -163,492 | -114,299 | -36,347 | -248,649 |
| Other Investing Activity | -162,253 | -77,064 | -22,273 | -16,337 | -346,168 |
| Investing Cash Flow | $-251,834 | $-5,600,779 | $-5,404,991 | $-89,790 | $-438,645 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 459,546 | 1,789,549 | 1,896,500 | 1,708,200 | N/A |
| Debt Issued | N/A | 3,206,982 | 3,246,381 | N/A | 248,500 |
| Debt Repayment | -42,669 | -45,336 | N/A | N/A | N/A |
| Common Stock Repurchased | -44,525 | -72,991 | -74,051 | -78,336 | -74,941 |
| Dividend Paid | -401,658 | -793,240 | -371,931 | -393,492 | -712,521 |
| Other Financing Activity | -46,976 | -119,673 | -72,824 | -31,573 | -107,991 |
| Financing Cash Flow | $-76,282 | $3,965,291 | $4,624,076 | $1,204,799 | $-646,952 |
| Exchange Rate Effect | 37,811 | 116,661 | 146,597 | 143,868 | 46,555 |
| Beginning Cash Position | 2,148,397 | 2,562,512 | 2,600,196 | 2,750,932 | 2,243,500 |
| End Cash Position | 1,938,739 | 1,727,050 | 2,304,552 | 4,098,855 | 2,710,894 |
| Net Cash Flow | $-209,658 | $-835,462 | $-295,644 | $1,347,923 | $467,393 |
| Free Cash Flow | |||||
| Operating Cash Flow | 80,640 | 683,373 | 338,666 | 89,045 | 1,506,435 |
| Capital Expenditure | -89,581 | -187,184 | -138,366 | -73,453 | -178,870 |
| Free Cash Flow | -8,941 | 496,189 | 200,300 | 15,593 | 1,327,565 |